Ipsen (OTCMKTS:IPSEY) PT Raised to €95.00

Ipsen (OTCMKTS:IPSEYGet Rating) had its price objective boosted by Barclays from €88.00 ($95.65) to €95.00 ($103.26) in a research note published on Thursday, The Fly reports. They currently have an underweight rating on the stock.

A number of other analysts have also recently issued reports on IPSEY. Credit Suisse Group boosted their price objective on Ipsen from €87.00 ($94.57) to €105.00 ($114.13) and gave the company a neutral rating in a research report on Friday, March 25th. AlphaValue raised Ipsen to a reduce rating in a research note on Thursday, February 17th. Societe Generale raised Ipsen from a hold rating to a buy rating in a research note on Thursday, January 6th. JPMorgan Chase & Co. lowered Ipsen from an overweight rating to a neutral rating in a research note on Tuesday, January 4th. Finally, Zacks Investment Research lowered Ipsen from a buy rating to a hold rating in a research note on Wednesday, December 29th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $76.33.

IPSEY opened at $30.41 on Thursday. Ipsen has a 1 year low of $21.71 and a 1 year high of $32.51. The stock’s 50 day simple moving average is $29.26 and its 200-day simple moving average is $26.22.

Ipsen Company Profile (Get Rating)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents.

See Also

The Fly logo

Analyst Recommendations for Ipsen (OTCMKTS:IPSEY)

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.